One of the earliest immunotherapies approved by the Food and Drug Administration (FDA) for the treatment of cancer was a vaccine called sipuleucel-T. It’s been used to treat metastatic prostate cancer since 2010.

Since then, the introduction of immune checkpoint inhibitors has revolutionized the field of cancer treatment. And patients with some types of cancer — such as melanoma and lung cancer — have benefitted greatly from that...